Research programme: proteasome inhibitors - Millennium
Latest Information Update: 15 May 2008
At a glance
- Originator Harvard University
- Mechanism of Action Proteasome inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 14 May 2008 Millennium Pharmaceuticals has been acquired by Takeda
- 15 Dec 1997 Preclinical development for Malaria in USA (Unknown route)